metastases, as shown by MRI. 28 In a follow-up phase II study presented at the American Society for Clinical Oncology 2013 Annual Meeting, among eight prostate cancer patients with BRCA1 or BRCA2 mutations, four (50%) had either complete or partial response to olaparib and one patient (25%) demonstrated stable disease for at least 8 weeks. These impressive results were consistent with the preclinical data of 'synthetic lethality' , where cancer cells with defective HRR are sensitive to additional blockage of DNA repair with PARP inhibitor. Given that familiar BRCA mutations are rare in prostate cancer, identifying sporadic genetic alterations that could diminish the HRR and sensitize prostate cancer cells to PARP inhibitor based therapy has been an area of active research.
Loss of PTEN and Rad51
The tumor suppressor PTEN negatively regulates the PI3K/AKT/ mTOR (phosphoinositide kinase-3/protein kinase B/mammalian target of rapamycin) tumor survival pathway. Data from array comparative genome hybridization and targeted exome sequencing have reported enrichment of loss of PTEN in metastatic prostate cancer. 9, 11 Preclinical studies with colon, breast and prostate cancer cell lines have shown that loss of PTEN was associated with reduced Rad51 levels and subsequent sensitivity to PARP inhibition. 17 Rad51 acts downstream of the BRCA1 and BRCA2 and is a key protein in the HRR pathway. 29 Such correlations between loss of PTEN and Rad51 level; however, were not observed in a recent study with radical prostatectomy samples. 30 Although one could argue that radical prostatectomy samples may not recapitulate the downstream events of PTEN loss in late-stage prostate cancer, a recent phase I study with PARP inhibitor niraparib/MK4827 did not observe associations between loss of PTEN and antitumor activities in sporadic metastatic prostate cancer patients. 31 With 23 CRPC patients (only one had documented BRCA mutation); this recently reported phase I study with niraparib/MK4827 had by far the largest prostate cancer cohort among the single-agent PARP inhibitor trials. Although no radiological responses were noted, nine of the 21 patients (43%) treated at either 290 or 300 mg day −1 had stable disease for a median duration of 254 days (range 124-375 days). 31 This is the first study to document clinical activity of a PARP inhibitor in sporadic CRPC. More importantly, this study took great effort to explore the association between clinical benefit and loss of PTEN expression or ETS rearrangement in circulating tumor cells as well as in tumor tissue. Although the marker studies are exploratory in this phase I trial, loss of PTEN by itself is probably not sufficient to predict defective HRR or sensitivity to PARP inhibition.
Among other potential biomarkers, reduced Rad51 levels have been linked to loss of PTEN and subsequent sensitivity to PARP inhibition in preclinical models. 17 As a key protein in HRR, mutation or copy number changes in Rad51 are rare; whereas, overexpression of Rad51 is common in cancer, particularly in cancers that harbor mutant p53. 32 Wild-type p53 can suppress Rad51 transcription either directly or indirectly. 33, 34 Other than p53 mutations, RB mutation is another frequent genetic event in metastatic CRPC. 11 Loss of functional RB could lead to enhanced E2F1 activity, and E2F1 has been shown to bind to Rad51 promoter and increases its transcription. 35 Overexpression of Rad51 in cancer cells with p53 or RB mutations could potentially rescue the HRR defects caused by BRCA mutation or loss of PTEN. [36] [37] [38] [39] The p53 and Rad51 status can be studied in formalin-fixed, paraffin-embedded samples with established immunohistochemistry protocols. Efforts are underway to detect Rad51 nuclear foci formation, a widely accepted marker for activation of the HRR pathway, in circulating tumor cells. Incorporating biomarkers like p53 and Rad51 in PARP inhibitor-based clinical trials would help to delineate the mechanism of prostate cancer cells' sensitivity or resistance to PARP inhibition.
Hypoxia and p53
Intratumoral hypoxia has been well-documented in prostate cancer, 40 and downregulation of DNA repair proteins like Rad51 and BRCA1 has been reported in prostate cancer cells grown under chronic hypoxia culture. 41, 42 Such downregulation of DNA repair proteins under chronic hypoxia could sensitize prostate cancer cells to PARP inhibitor. Although preclinical studies have reported increased cell death and DNA damage in non-prostate cancer cell lines grown under hypoxia, 43 our study showed that prostate cancer cells with mutant p53 were resistant to PARP inhibitor veliparib and the DNA damaging topoisomerase I inhibitor irrinotecan/CPT-11 under hypoxia (Figure 1) . Our data support that hypoxia contributes to drug resistance, but such resistance was not due to increased mutation rate secondary to diminished DNA repair as previously suggested. 25, 44, 45 Upregulation of Rad51 was observed soon after challenging these p53-mutant prostate cancer cells with DNA-damaging agents (Figure 1) . We also assessed genomic stability by looking at chromosomal copy number alterations with nCounter molecular karyotyping. When compared to the untreated control under chronic hypoxia culture, we did not detect increased chromosomal copy number alterations in PC3 cells with up to 3 weeks of hypoxia culture and veliparib treatment (Figure 2) . Furthermore, recent high-throughput sequencing studies have reported that mutation rates in metastatic CRPC (2.0 mutations per mega base) were not significantly increased compared to primary tumors (0.9-1.5 mutations per mega base). The enrichment of genomic instability in late-stage prostate cancer could result from increasing tumor heterogeneity after a prolonged selection process by the tumor microenvironment and treatment.
As a DNA damage checkpoint gene, p53 is among the most frequently mutated genes in cancer. Based on the International Agency for Research on Cancer TP53 database, the frequency of p53 mutations is 17.5% among 1106 sporadic prostate cancers. In the study by Barbieri et al., six missense mutations and one frameshift mutation in p53 were detected by exome sequencing of 111 treatment-naïve primary prostate cancers. 15 Although this 6% mutation frequency is lower than the historical data, mutation in p53 was the second most common mutation in this dataset. The exome sequencing study by Grasso et al. 11 reported two point mutations and two frame shift mutations in 11 treatment-naïve high-grade primary prostate cancers (36% mutation frequency) and 14 point mutations and five frame shift mutations in 50 heavily treated lethal CRPC patients (38% mutation frequency). Copy number loss of p53 was also observed in nine of these 50 lethal cases. 15 Given that wild-type p53 can suppress the transcription of Rad51, 33, 34 prostate cancer cells with mutant p53 can evade not only apoptosis but will likely have more effective HRR due to lack of suppression of Rad51 transcription by wild-type p53.
Disruption of transcriptional regulation with parp inhibitor
As an abundant and ubiquitous nuclear protein, PARP1 has been shown to bind to promoters and enhancers and to interact with a wide variety of proteins that regulate gene transcription. 46 Most of these regulations require its enzymatic activity, i.e. poly (ADP-ribosyl) ation. Other than diminishing DNA repair, emerging preclinical data have indicated that PARP inhibitor can disrupt transcriptional regulation by AR and the ETS fusion protein. 16, 27 The recurrent fusions between the androgen-regulated TMPRSS2 and ETS transcription factor genes (primarily ERG) occur in about 50% of primary prostate cancers. 10, 12 ERG was recently shown to interact with PARP1, with PARP1 activity required for ERG-mediated transcription, cell invasion and metastasis. 16 Inhibition of PARP1 enhanced DNA double-strand breaks induced by ERG overexpression and slowed the growth of ERG-positive prostate cancer cells. 16 Such enhanced PARP inhibitor activity can be contributed to downregulation of ERG-mediated transcription, the genomic instability in ERG fusion-positive tumors, or a combination of both. Another study with prostate cancer cell line models showed that PARP inhibition reduced AR occupancy of chromatin and suppressed the expression of AR target genes, including UBE2C, a key regulator of cell cycle progression. 27 Unlike its interaction with ERG, PARP1 occupied the AR target gene promoter without forming a complex with AR. The authors also reported that treatment with PARP inhibitor slowed down the proliferation (Ki67 index) of prostate cancer cells grown in an ex vivo culture system. 27 Despite this strong preclinical rationale for targeting ETS fusion-positive prostate cancer with PARP inhibitor, no correlations were observed between ETS gene rearrangement and antitumor activities (time to disease progression, PSA response rate or decline in circulating tumor cells) in the phase I study with niraparib in 23 CRPC patients. 31 As an early genetic alteration in prostate cancer, ETS 
RATIONALE FOR PARP INHIBITOR-BASED COMBINATION THERAPIES
Grade 3 or 4 toxicities are rare in early-phase clinical trials with single-agent PARP inhibitor. 28, 31 This has led to preclinical and clinical studies with various PARP inhibitor-based regimens in prostate cancer with the goal to maximize the DNA damage or to disrupt the transcriptional regulation through AR and ETS fusion proteins.
Combining the PARP inhibitor with cytotoxic chemotherapy PARP inhibitor veliparib/ABT-888 enhanced the activity of multiple DNA-damaging agents, including cisplatin, carboplatin, cyclophosphamide, irinotecan and temozolomide, in various solid tumor preclinical models. 47 Among these agents, temozolomide was shown to have the most synergistic antitumor activity when combined with veliparib/ABT-888. 48 As an alkylating agent, temozolomide induces DNA methylation at guanine O6 (O6-MeG), guanine N7 (N7-MeG) and adenine N3 (N3-MeA). BER is involved in repairing the N3-MeA and N7-MeG DNA adducts. 49 Blocking BER with PARP inhibitor would therefore enhance the DNA damage caused by temozolomide. Combining veliparib with temozolomide, not temozolomide alone, inhibited the growth of orthotopic and intratibial mouse prostate cancer xenografts made of luciferase-labeled PC3 cells. 48 The veliparib and temozolomide combination was subsequently tested in patients with metastatic CRPC who have failed up to two non-hormonal systemic therapies in a multi-institutional pilot study (NCT01085422). The primary objective of this study is to assess the efficacy of this combination based on the rate of PSA decline of 30% or greater. Despite the promising preclinical activity, only two of the 25 evaluable patients had a confirmed PSA response: 1 had a 37% decrease in PSA, while the other had a 96% decrease in PSA and a 40% reduction in tumor size. Four of the 25 patients had stable disease for a minimum of 4 months. Median progression-free survival was 2.1 months. Of note, temozolomide showed no activity as a single agent in prostate cancer. The updated results and biomarker studies of this trial are not published yet. If feasible, a comprehensive genetic analysis with exome sequencing on the patient with both PSA and radiographic responses may help uncover genetic alterations that sensitize his CRPC to the temozolomide-veliparib combination.
Although none of the DNA-damaging chemotherapy agents has been approved for prostate cancer treatment, such agents have been used to treat small cell prostate cancer and 'anaplastic' prostate cancer. Most recently, the carboplatin-docetaxel combination followed by cisplatin and etoposide at disease progression have shown meaningful clinical activity in a phase II study of 120 patients who met the predefined criteria of 'anaplastic' prostate cancers. 50 For the majority of these patients, their cancer became castration resistant within 6 months of androgen deprivation therapy (45.6%), with a bulky (≥5 cm) lymphadenopathy or bulky (≥5 cm) high-grade (Gleason ≥ 8) tumor mass in the prostate or pelvis (43%). This subset of prostate cancer shares several clinical features of treatment-related neuroendocrine prostate cancer (NEPC) and has a very poor prognosis. Using next-generation RNA-sequencing and oligonucleotide arrays, Beltran et al. profiled seven NEPC, 30 prostate adenocarcinoma and five benign prostate tissue samples and found significant overexpression and gene amplification of AURKA and MYCN in NEPC compared to primary prostate cancer. This finding was validated from a large cohort of prostate tumors with immunohistochemistry and fluorescent in situ hybridization. 51 A follow-up study also indicated that prostate adenocarcinomas with AURKA and MYCN coamplification are at risk to develop NEPC after androgen deprivation therapy. 52 It would be important to check AURKA and MYCN status in the 'anaplastic' prostate cancers and correlate these amplifications with their response to chemotherapy in the clinical study by Aparicio et al. If feasible, assessment of DNA damage and DNA repair markers in pre-and posttreatment tumor samples would also be informative. Based on its fast proliferation and the rapid development of treatment resistance, studies of anaplastic prostate cancer at the DNA level will likely reveal genetic alterations in cell cycle checkpoint and DNA repair genes. PARP inhibitor may enhance the chemotherapy-induced DNA damage in anaplastic prostate cancer.
Combining the PARP inhibitor with androgen deprivation therapy
The success of abiraterone and enzalutamide in treating metastatic CRPC indicates persistent AR signaling in this late stage of prostate cancer. Based on the emerging role of PARP1 in mediating transcriptional regulation by AR and the ETS fusion protein, 16 ,27 a multicenter randomized phase II trial is evaluating whether adding the PARP inhibitor veliparib to abiraterone acetate and prednisone would improve the PSA response rate (primary objective) of the standard abiraterone acetate and prednisone regimen in patients with metastatic CRPC (NCT01576172). The availability of metastatic tumor tissue that is evaluable for ETS fusion status is required for this study, and a logistic model will be used to determine the association of ETS fusion status with the PSA response in the veliparib-abiraterone-prednisone arm. PSA decline rate, objective response rate, progression-free survival and toxicity are among the secondary objectives. This study will provide the much needed clinical validation on the value of ETS gene rearrangement as a predicative biomarker for PARP inhibitor-based therapy for metastatic CRPC.
In addition to disruption of AR transcription, combining veliparib with abiraterone for ETS fusion-positive prostate cancer could lead to enhanced DNA damage and apoptosis, as indicated in the preclinical study by Brenner et al. 16 This potential benefit, however, will not be well captured by PSA response rate or by progression-free survival (secondary endpoint) of the NCT01576172 study. Even if this combination improves the PSA response rate, it is still unclear whether this combination is more effective or safer than combining abiraterone with enzalutamide, which is being tested in a phase II study for patients with progressive metastatic CRPC in the bone (NCT01650194). Assessment of DNA damage in posttreatment tumor biopsies or circulating tumor cells, if built into the NCT01576172 study, would help to distinguish the valiparib-abiraterone combination from the enzalutamide-abiraterone combination.
Combining the PARP inhibitor with radiotherapy A preclinical study with prostate cancer cell lines reported that combining the PARP inhibitor rucaparib with radiation enhanced the DNA damage and antitumor effects compared to radiation alone. 53 The strongest synergistic activities were observed in LNCaP and VCaP cells, which express ETS fusion proteins. Although combining a PARP inhibitor with radiation would be an attractive strategy to increase the cure rate of newly diagnosed ETS fusion-positive nonmetastatic prostate cancer, overtreatment and long-term safety are the main concerns of testing this strategy in the clinic. The biochemical recurrence rate after initial definitive surgery or radiation is between 20% and 30%. Only a portion of patients with biochemical recurrence will die from prostate cancer. There is also a lack of long-term safety data on the PAPR inhibitors tested in early-phase clinical trials. Enhanced DNA damage with a PARP Asian Journal of Andrology inhibitor and radiation could lead to genomic instability and more aggressive prostate cancer when it recurs. Secondary malignancy would be another concern.
Combining PARP inhibitors with radiopharmaceuticals like radium 223 could be a reasonable combination for patients with metastatic CRPC to the bone, as concerns for overtreatment or for long-term safety are insignificant at this lethal stage of prostate cancer. If markers like p53 mutation, ETS gene rearrangement and/or loss of PTEN are able to identify the late-stage prostate cancers enriched with genomic instability, combining radium 223 with a PARP inhibitor could be more effective than combing radium 223 with docetaxel, enzalutamide or abiraterone in this group of lethal prostate cancer.
CONCLUSIONS
The activity of the PARP inhibitor niraparib in sporadic prostate cancer provides a strong clinical rationale for developing PARP inhibitor-based therapies for metastatic CRPC. As presently shown, loss of PTEN or presence of ETS gene rearrangement by itself is unlikely to be sufficient to predict response to PARP inhibitor-based therapies. Other than blocking DDR, PARP inhibitors have been shown to disrupt transcriptional regulation through AR and ETS fusion proteins in CRPC preclinical models. This preclinical finding is being tested in an ongoing phase II study of abiraterone with or without veliparib in patients with metastatic CRPC (NCT01576172). Whether this combination can lead to greater PSA response than abiraterone alone in ETS fusion-positive prostate cancer remains to be seen. Moving forward, we will continue to learn from PARP inhibitor-based trials and evaluate the biomarkers being embedded in these studies. Based on the recent success of platinum-based regimens in treating anaplastic prostate cancer, I would propose focusing future PARP inhibitor-based trials and biomarker studies on this subtype of lethal prostate cancer where there is truly an unmet need.
